France’s traditionally strong economy and its relationship with the European continent define the makeup of its unique legal market. Centred on the capital, a significant number of international Anglo-Saxon law firms have their largest continental office based in the city, with some having been established around half a century ago. Their primary competition, aside from each other, is the large and highly competitive independent French firms. However, a more recent development in the French capital has been the relatively strong growth and diversification of local and boutique law firms, which can often be seen acting on some of the highest-profile matters in the country.
In each of our 32 chapter analyses we provide a more detailed overview of the leading lawyers in our research, as well as identifying the most highly regarded individuals.
At the beginning of 2015, the Swiss government continued to dismantle its legendary bank secrecy laws. Despite finance minister Hans-Rudolf Merz’s insistence in 2009 that Switzerland would never revise these, the changes appear to have been made following the 2009 UBS scandal which saw the country’s largest bank being fined $780 million for aiding foreign tax evaders. As a result, the country has faced ongoing pressure from neighbouring EU and US authorities for more transparency and tax compliance. While the globalisation of information appears to be a worldwide trend, the effect of these changes on a country such as Switzerland, which has built one of the most advanced banking systems in the world on the back of confidentiality, will be remarkable to see for interested parties both within the country and on a global scale.
The eighth edition of this ever-expanding publication features over 1,200 listings from 417 law firms across four distinct areas of research: patent litigation, regulatory, product liability defence and transactional. In this analysis of the life sciences legal market, the following individuals and law firms stand out as the most highly regarded in our research process.
The life sciences industry is continuing to evolve in a time of economic uncertainty, demographic transformation and technological innovation. Governments are moving towards stricter regulatory regimes, and more austere pricing and reimbursement policies. The spiralling cost of R&D, along with technological innovations, continue to push life sciences companies into partnering transactions, as well as driving M&A deal activity. Meanwhile, the burgeoning biopharmaceutical industry is now faced with the emergence of game-changing biosimilars. It is a challenging time for life sciences companies and legal teams alike.
With the contentious proposed revisions of the French civil code due to come into action in early 2016, it’s set to be a landmark year for the project finance sector in France. Initial fears that the revisions will nullify commercial contracts have been offset by the belief that the revisions will modernise and augment French contract law. Africa remains an active region for French specialists in the field, with local energy and infrastructure projects continuing to steam ahead. This chapter identifies 20 key performers in the field.
It is not possible to buy entry into any Who's Who Legal publication
Nominees have been selected based upon comprehensive, independent survey work with both general counsel and private practice lawyers worldwide. Only specialists who have met independent international research criteria are listed.